author-photo

Peter L. Turecek

Takeda Pharmaceutical Company

10

Papers

46

Citations

Citation Trend

Filter By

Papers (10) Sort By

Journal Conference Others

A systematic review of physical activity in people with haemophilia and its relationship with bleeding phenotype and treatment regimen

2021 Haemophilia
Show All
- Source
- Cite
- Save
Citations (0)
Recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19.

2021 Thrombosis Research
Show All
- Source
- Cite
- Save
Citations (13)
Biological mechanisms underlying inter-individual variation in factor VIII clearance in haemophilia.

2020 Haemophilia
Show All
- Source
- Cite
- Save
Citations (6)
PEG–protein conjugates: nonclinical and clinical toxicity considerations

2020
- Peter L. Turecek
- Jürgen Siekmann
Show All
- Source
- Cite
- Save
Citations (5)
Polysialylation of human coagulation factor VIII

2020
- Jürgen Siekmann
- Peter L. Turecek
Show All
- Source
- Cite
- Save
Citations (0)
Origins, Development, Current Challenges and Future Directions with Activated Prothrombin Complex Concentrate for the Treatment of Patients with Congenital Haemophilia with Inhibitors

2020 Hamostaseologie
Show All
- Source
- Cite
- Save
Citations (3)
PEGylation of human coagulation factor VIII and other plasma proteins

2020
- Jürgen Siekmann
- Peter L. Turecek
Show All
- Source
- Cite
- Save
Citations (0)
Evaluation of factor VIII polysialylation: Identification of a longer-acting experimental therapy in mice and monkeys

2019 Journal of Pharmacology and Experimental Therapeutics
Show All
- Source
- Cite
- Save
Citations (3)
Evolution of replacement therapy for von Willebrand dicsease: From plasma fraction to recombinant von Willebrand factor

2019 Blood Reviews
Show All
- Source
- Cite
- Save
Citations (16)
Polysialic acid-mediated activity measurement of polysialylated recombinant coagulation factor VIII

2019 Journal of Pharmaceutical Sciences
Show All
- Source
- Cite
- Save
Citations (0)